Skip to Content

Posts tagged with "Press Coverage"

  • Press Coverage

    Freedom of the Press: Science Reporting Division

    There’s been an interesting dispute playing out over the last few weeks about science reporting. Here’s a summary, but I’ll give one as well: it all got started with David Kroll, aka “Abel Pharmboy” of the Terra Sigillata blog (and another, Take as Directed). On that latter site, he’d written about science articl… Read More
  • In Silico

    Foldit Notches a Protein Structure Success (And Some Failures)

    I wrote last year about Foldit, a collaborative effort to work on protein structure problems that’s been structured as an open-access game. Now the team is back with another report on how the project is going, and it’s interesting stuff. The headlines have generally taken the “Computer Gamers Solve Incredible Protein Problem That… Read More
  • Drug Development

    2011 Drug Approvals Are Up: We Rule, Right?

    I’ve been meaning to comment on this article from the Wall Street Journal – the authors take a look at the drug approval numbers so far this year, and speculate that the industry is turning around. Well, put me in the “not so fast” category. And I have plenty of company there. Neither Bruce Booth… Read More
  • Chemical News

    The Public Perception of Chemistry

    I wanted to call attention to another blog roundtable, on several subjects related to how nonchemists see us and our business. The first post (at ScienceGeist) is on chemical safety (industrial chemicals = bad?). Day 2, at ChemJobber, is on whether the general public has any good idea of not only what chemists do (we… Read More
  • Press Coverage

    For Responsible Stem Cell Reporting. . .

    . . .you either have to go to the specialty press, or (sometimes) to the last couple of paragraphs of a mainstream article. For several years now, it’s been hard to think of any medical field that’s been more relentlessly overhyped than stem cell therapy (a worst-case example was its appearance in the 2004 elections… Read More
  • Press Coverage

    Telling Everyone What It’s Like

    Here’s a op-ed from Josh Bloom (ex-Wyeth) in the New York Post that will resonate with a lot of people out there. A sample: The folks at Scientific American have launched “1,000 Scientists in 1,000 Days” — a program to bring together scientists, teachers and students to improve America’s “dismal” showing am… Read More
  • Press Coverage

    The Failure of Modern Medicine?

    I was going to take a shot at this article myself, a piece in The Atlantic called “The Triumph of New Age Medicine”. But Matthew Herper at Forbes has done the job for me. The original article advances the thesis that modern medicine isn’t doing much for chronic diseases, which is why people are turning… Read More
  • Cardiovascular Disease

    Cardiac Hope and Cardiac Hype

    There have been quite a few headlines over the last few days like this one: “A New Drug Makes Hearts Repair Themselves”. Unfortunately, that’s not quite true. Not yet. It’s this paper in Nature that’s getting the attention, and it is a very interesting one. The authors have identified a population of progenitor cells i… Read More
  • Press Coverage

    Even Worse Than Reality

    I found this article in The American Scholar via Arts and Letters Daily, entitled “Flacking for Big Pharma”. As you might have possibly guessed from the title, it’s a broadside against the advertising practices of the drug industry, and particularly against its interactions with physicians and the medical journals. And I’ll… Read More
  • Business and Markets

    What A Fool Believes

    What’s going on over at Slate, anyway? So far this week we’ve been talking about that Timothy Noah article over there publicizing the bizarre Light and Warburton estimate for drug development. Now one of their house blogs erupts with a geyser of idiocy about the looming patent cliff in the industry: So this sudden terrible… Read More
...456...